| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1021361499 |
| P356 | DOI | 10.1007/S11910-014-0511-3 |
| P698 | PubMed publication ID | 25407133 |
| P2093 | author name string | Fernando Pagan | |
| Laxman Bahroo | |||
| Reversa Mills | |||
| P2860 | cites work | Parkinson's disease: clinical features and diagnosis | Q22242021 |
| Treatment of dystonia. | Q30566734 | ||
| Drooling of saliva: a review of the etiology and management options | Q33229753 | ||
| Constipation and paradoxical puborectalis contraction in anismus and Parkinson's disease: a dystonic phenomenon? | Q33630384 | ||
| Increased stability of airflow following botulinum toxin injection | Q33709464 | ||
| Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders | Q34326147 | ||
| Dystonia and parkinsonism | Q34328686 | ||
| Phenomenology and classification of dystonia: a consensus update | Q34343247 | ||
| Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations | Q34410406 | ||
| Camptocormia: pathogenesis, classification, and response to therapy | Q34441398 | ||
| Dystonia in Parkinson's disease | Q34585274 | ||
| Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology | Q34776040 | ||
| The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease | Q48398056 | ||
| Neurotoxin injection for movement disorders | Q50270265 | ||
| Botulinum toxin A may be efficacious as treatment for jaw tremor in Parkinson's disease | Q50278285 | ||
| Swallowing abnormalities and their response to treatment in Parkinson's disease. | Q52868399 | ||
| Use of botulinim toxin-A for the treatment of overactive bladder symptoms in patients with Parkinsons's disease. | Q53068301 | ||
| A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. | Q53890864 | ||
| Botulinum toxin A injections for the treatment of hand tremors. | Q54021740 | ||
| Botulinum toxin treatment of tremors | Q54075638 | ||
| Outlet type constipation in Parkinson's disease: results of botulinum toxin treatment | Q58874800 | ||
| Treatment of outlet obstruction constipation in Parkinson's disease with botulinum neurotoxin A | Q58874812 | ||
| A randomized trial of botulinum toxin A for treatment of drooling | Q60360007 | ||
| Sensory integration in writer’s cramp: Comparison with controls and evaluation of botulinum toxin effect | Q62018178 | ||
| Botulinum toxin type A for drooling in Parkinson's disease: A double-blind, randomized, placebo-controlled study | Q63436954 | ||
| Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy | Q64760933 | ||
| Non-invasive assessment of swallowing and respiration in Parkinson's disease | Q64764338 | ||
| Botulinum toxin in the treatment of writer's cramp: a double-blind study | Q70537913 | ||
| Effect of neuromuscular activity on the response to botulinum toxin injections in spasmodic dysphonia | Q70873325 | ||
| Comparison of botulinum toxin injection procedures in adductor spasmodic dysphonia | Q71238210 | ||
| Botulinum toxin A in non-dystonic tremors | Q71289995 | ||
| A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor | Q71301123 | ||
| Asymptomatic swallowing disorders in elderly patients with Parkinson's disease: a description of findings on clinical examination and videofluoroscopy in sixteen patients | Q72187377 | ||
| Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism | Q73472804 | ||
| Long-term results and prognostic factors in the treatment of achalasia with botulinum toxin | Q74594491 | ||
| A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease | Q75246324 | ||
| Randomized controlled trial of intrasphincteric botulinum toxin A injection versus balloon dilatation in treatment of achalasia cardia | Q77703323 | ||
| Sweating dysfunction in Parkinson's disease | Q79364972 | ||
| Treatment of advanced Parkinson's disease | Q80069517 | ||
| Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia | Q80573879 | ||
| Oromandibular dystonia | Q80773837 | ||
| Botulinum toxin type A in patients with Parkinson's disease and refractory overactive bladder | Q84596109 | ||
| Gastrointestinal dysfunction in Parkinson’s disease | Q85006876 | ||
| Botulinum toxin and gastrointestinal tract disorders: panacea, placebo, or pathway to the future? | Q34978565 | ||
| Review article: botulinum toxin in the therapy of gastrointestinal motility disorders | Q35171808 | ||
| A multicentre randomised study of intrasphincteric botulinum toxin in patients with oesophageal achalasia. GISMAD Achalasia Study Group. | Q35360275 | ||
| Treatment with botulinum neurotoxin of gastrointestinal smooth muscles and sphincters spasms | Q35694013 | ||
| Botulinum toxin in clinical practice | Q35807826 | ||
| Striatal deformities of the hand and foot in Parkinson's disease | Q36166588 | ||
| Botulinum toxin for writer's cramp: a randomised, placebo-controlled trial and 1-year follow-up | Q36226922 | ||
| Predictive value of clinical indices in detecting aspiration in patients with neurological disorders | Q36317197 | ||
| Treatment of focal dystonias with botulinum neurotoxin | Q36662999 | ||
| Treatment of focal hyperhidrosis | Q36765098 | ||
| Long-term efficacy and safety of botulinum toxin injections in dystonia | Q36807185 | ||
| Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease | Q36847246 | ||
| Medical management of levodopa-associated motor complications in patients with Parkinson's disease | Q36881415 | ||
| Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology | Q37155202 | ||
| Disease-oriented approach to botulinum toxin use. | Q37346370 | ||
| Flu-like symptoms following botulinum toxin therapy | Q37881203 | ||
| Parkinson's disease: the non-motor issues | Q37899473 | ||
| Botulinum toxins in the treatment of primary focal dystonias | Q37984176 | ||
| Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders | Q38062276 | ||
| Oromandibular dystonia: long-term management with botulinum toxin | Q38152357 | ||
| Bladder function of patients with Parkinson's disease | Q38191267 | ||
| Effects of botulinum toxin injections on speech in adductor spasmodic dysphonia | Q38594341 | ||
| Long-term follow-up of achalasia patients treated with botulinum toxin | Q39408640 | ||
| Randomized controlled trial comparing botulinum toxin injection to pneumatic dilatation for the treatment of achalasia | Q39414808 | ||
| Approach to the treatment of limb disorders with botulinum toxin A. Experience with 187 patients | Q39463815 | ||
| Botulinum toxin for achalasia: long-term outcome and predictors of response | Q39465926 | ||
| “Off” painful dystonia in Parkinson's disease treated with botulinum toxin | Q42277562 | ||
| Effectiveness of BoNT A in Parkinson's disease upper limb tremor management | Q42615066 | ||
| Flu-like symptoms and associated immunological response following therapy with botulinum toxins | Q43736034 | ||
| Questionnaire-based assessment of pelvic organ dysfunction in Parkinson's disease | Q43746684 | ||
| Idiopathic cervical dystonia: clinical characteristics | Q44510674 | ||
| Botulinum toxin therapy for limb dystonias | Q44590039 | ||
| Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study | Q44808533 | ||
| The current and projected economic burden of Parkinson's disease in the United States | Q44988421 | ||
| Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia. | Q46028429 | ||
| Effect of botulinum toxin injection on nocturnal bruxism: a randomized controlled trial | Q46185329 | ||
| Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial | Q47729604 | ||
| Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related drooling | Q47919826 | ||
| Ultrasound-guided versus 'blind' intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson's disease | Q47995531 | ||
| P433 | issue | 1 | |
| P921 | main subject | Parkinson's disease | Q11085 |
| P304 | page(s) | 511 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | Current Neurology and Neuroscience Reports | Q18206211 |
| P1476 | title | An update on the use of botulinum toxin therapy in Parkinson's disease | |
| P478 | volume | 15 |
| Q36115292 | A Double-Blind Randomized Controlled Trial Investigating the Most Efficacious Dose of Botulinum Toxin-A for Sialorrhea Treatment in Asian Adults with Neurological Diseases. |
| Q38845546 | Nondopaminergic treatments for Parkinson's disease: current and future prospects |
| Q37400295 | Occurrence of Dysphagia Following Botulinum Toxin Injection in Parkinsonism-related Cervical Dystonia: A Retrospective Study |
| Q38656025 | Oropharyngeal dysphagia: manifestations and diagnosis |
| Q38592741 | Parkinson's Disease and Gastrointestinal Non Motor Symptoms: Diagnostic and Therapeutic Options - A Practise Guide |
Search more.